Shionogi & Co., Ltd. (TYO:4507)
2,854.00
+27.00 (0.96%)
Sep 14, 2026, 3:30 PM JST
Shionogi & Revenue
Shionogi & had revenue of 163.31B JPY in the quarter ending June 30, 2026, with 63.67% growth. This brings the company's revenue in the last twelve months to 563.21B, up 27.86% year-over-year. In the fiscal year ending March 31, 2026, Shionogi & had annual revenue of 499.68B with 14.01% growth.
Revenue (ttm)
563.21B
Revenue Growth
+27.86%
P/S Ratio
4.31
Revenue / Employee
90.50M
Employees
6,223
Market Cap
2.43T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 499.68B | 61.41B | 14.01% |
| Mar 31, 2025 | 438.27B | 3.19B | 0.73% |
| Mar 31, 2024 | 435.08B | 8.40B | 1.97% |
| Mar 31, 2023 | 426.68B | 91.55B | 27.32% |
| Mar 31, 2022 | 335.14B | 37.96B | 12.77% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.62T |
| Eisai | 857.06B |
| Sumitomo Pharma | 474.79B |
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 203.79B |
| Tsumura & Co. | 199.23B |
| Nippon Shinyaku | 180.29B |
| Mochida Pharmaceutical | 122.04B |
Shionogi & News
- 5 days ago - Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026 - Business Wire
- 17 days ago - Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats - Business Wire
- 6 weeks ago - Shionogi & Quarterly report: Q1 2027 - Filings
- 6 weeks ago - Shionogi & Slides: Q1 2027 - Filings
- 6 weeks ago - Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS - Business Wire
- 2 months ago - FDA Accepts Shionogi's sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria - Business Wire
- 2 months ago - Shionogi & Slides: Investor presentation - Filings
- 3 months ago - Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure - Business Wire